Physician profile
Mark D Garfield
NPI 1669555355
$11,580.63
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,503 · 2020: $1,867 · 2021: $2,210 · 2022: $2,497 · 2023: $2,472 · 2024: $31.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,719.31 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $1,871.05 | 2019-2023 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $1,462.24 | 2019-2023 | Breztri, Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $898.11 | 2019-2023 | Ofev |
| Philips North America LLC | $668.73 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $455.08 | 2019-2023 | Opsumit, Uptravi |
| Electromed, INC. | $453.34 | 2019-2023 | Smartvest |
| Genzyme Corporation | $307.42 | 2019-2023 | |
| Amgen INC. | $259.08 | 2021-2023 | Tezspire |
| Harmony Biosciences LLC | $248.21 | 2022-2023 | Wakix |
| Advanced Respiratory, INC | $240.13 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $193.64 | 2019 | |
| Insmed, INC. | $192.55 | 2021-2023 | Arikayce |
| Novartis Pharmaceuticals Corporation | $191.29 | 2019-2023 | |
| Mylan Specialty L.P. | $171.96 | 2022-2023 | Yupelri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $159.04 | 2019-2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $150.16 | 2019-2022 | |
| Inspire Medical Systems, INC. | $119.24 | 2023-2024 | Inspire |
| Baxter Healthcare | $105.90 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Janssen Pharmaceuticals, INC | $76.76 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $72.76 | 2021-2023 | Zerbaxa, Dificid, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $64.25 | 2021-2023 | Cuvitru |
| Axsome Therapeutics, INC. | $62.01 | 2023 | Sunosi |
| Nabriva Therapeutics, Plc | $61.88 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.04 | 2019-2021 | |
| Covis Pharma Gmbh | $56.27 | 2022-2023 | |
| Resmed Corp | $44.31 | 2019 | |
| Mallinckrodt Hospital Products INC. | $43.29 | 2023 | Acthar |
| Allergan, INC. | $43.09 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $38.83 | 2021-2022 | |
| Viiv Healthcare Company | $35.23 | 2023 | Apretude |
| Shire North American Group INC | $21.97 | 2019 | |
| Cmp Pharma, INC. | $17.94 | 2021 | |
| Abbvie INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Garfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.